The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.

##STR00001##

The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.

##STR00001##

Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). The present invention reveals that quinacrine directly binds to G4 RNAs found in genomic RNA of the COVID-19 virus, showing antiviral activity against COVID-19 using in vitro cell culture systems. An object of the present invention is thus a new pharmaceutical composition of quinacrine for the treatment of COVID-19. Another object of the invention is a method for administering quinacrine by various routes specifically for treatment, including oral administration, sterile intravenous injection, and others.

Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). The present invention reveals that quinacrine directly binds to G4 RNAs found in genomic RNA of the COVID-19 virus, showing antiviral activity against COVID-19 using in vitro cell culture systems. An object of the present invention is thus a new pharmaceutical composition of quinacrine for the treatment of COVID-19. Another object of the invention is a method for administering quinacrine by various routes specifically for treatment, including oral administration, sterile intravenous injection, and others.

The present technology relates to compounds that inhibit human Ly6K and homologs thereof. Also disclosed are methods of using such compounds to: inhibit activity of a Ly6K protein in a cell; decrease migration, colony formation, and/or proliferation of a cell; modulate expression of a gene in a cell, reduce suppression of the immune response to cancer in a subject, decrease tumorigenic growth of a cancer in a subject, and treat or prevent in a subject a disorder mediated by Ly6K protein.

The present technology relates to compounds that inhibit human Ly6K and homologs thereof. Also disclosed are methods of using such compounds to: inhibit activity of a Ly6K protein in a cell; decrease migration, colony formation, and/or proliferation of a cell; modulate expression of a gene in a cell, reduce suppression of the immune response to cancer in a subject, decrease tumorigenic growth of a cancer in a subject, and treat or prevent in a subject a disorder mediated by Ly6K protein.

We disclose novel asymmetric bis-acridines with antitumour activity. These compounds are useful for use in pharmaceuticals, particularly in the treatment or the prevention of neoplasms.

We disclose novel asymmetric bis-acridines with antitumour activity. These compounds are useful for use in pharmaceuticals, particularly in the treatment or the prevention of neoplasms.

The present invention provides therapeutic strategies for treatment of severe debilitating diseases associated with IFN-I due to cGAS activation. In one aspect, the invention provides compounds of Formula (I): [Formula should be inserted here] and pharmaceutical uses thereof. In another aspect, the invention provides methods for treating an autoimmune disease or a monogenic disorder by administering an effective amount of a compound of Formula (I).

##STR00001##

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):(I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A is a heterocyclic or heteroaryl ring, and R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, A, G.sup.1, G.sup.2, L.sup.1, L.sup.2, m.sup.1, m.sup.2, and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

##STR00001##